These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 37993134)

  • 1. Discovery of Anti-SARS-CoV-2 Nsp9 Binders from Natural Products by a Native Mass Spectrometry Approach.
    Quinn RJ; Mak T; Littler DR; Rossjohn J; Liu M
    J Nat Prod; 2023 Dec; 86(12):2630-2637. PubMed ID: 37993134
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A natural product compound inhibits coronaviral replication in vitro by binding to the conserved Nsp9 SARS-CoV-2 protein.
    Littler DR; Liu M; McAuley JL; Lowery SA; Illing PT; Gully BS; Purcell AW; Chandrashekaran IR; Perlman S; Purcell DFJ; Quinn RJ; Rossjohn J
    J Biol Chem; 2021 Dec; 297(6):101362. PubMed ID: 34756886
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Affinity selection-mass spectrometry in the discovery of anti-SARS-CoV-2 compounds.
    van Breemen RB; Muchiri RN
    Mass Spectrom Rev; 2024; 43(1):39-46. PubMed ID: 35929396
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inhibition of SARS-CoV-2 Nsp9 ssDNA-Binding Activity and Cytotoxic Effects on H838, H1975, and A549 Human Non-Small Cell Lung Cancer Cells: Exploring the Potential of
    Su HH; Lin ES; Huang YH; Lien Y; Huang CY
    Int J Mol Sci; 2024 Jun; 25(11):. PubMed ID: 38892307
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Binding Studies of the Prodrug HAO472 to SARS-Cov-2 Nsp9 and Variants.
    Liu M; Littler DR; Rossjohn J; Quinn RJ
    ACS Omega; 2022 Mar; 7(8):7327-7332. PubMed ID: 35224406
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Structure-based drug repurposing for targeting Nsp9 replicase and spike proteins of severe acute respiratory syndrome coronavirus 2.
    Chandel V; Sharma PP; Raj S; Choudhari R; Rathi B; Kumar D
    J Biomol Struct Dyn; 2022 Jan; 40(1):249-262. PubMed ID: 32838660
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Backbone chemical shift assignments for the SARS-CoV-2 non-structural protein Nsp9: intermediate (ms - μs) dynamics in the C-terminal helix at the dimer interface.
    Buchko GW; Zhou M; Craig JK; Van Voorhis WC; Myler PJ
    Biomol NMR Assign; 2021 Apr; 15(1):107-116. PubMed ID: 33392924
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Polypharmacology of some medicinal plant metabolites against SARS-CoV-2 and host targets: Molecular dynamics evaluation of NSP9 RNA binding protein.
    Bandyopadhyay S; Abiodun OA; Ogboo BC; Kola-Mustapha AT; Attah EI; Edemhanria L; Kumari A; Jaganathan R; Adelakun NS
    J Biomol Struct Dyn; 2022; 40(22):11467-11483. PubMed ID: 34370622
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In silico evaluation of lapachol derivatives binding to the Nsp9 of SARS-CoV-2.
    Junior NN; Santos IA; Meireles BA; Nicolau MSP; Lapa IR; Aguiar RS; Jardim ACG; José DP
    J Biomol Struct Dyn; 2022 Aug; 40(13):5917-5931. PubMed ID: 33478342
    [TBL] [Abstract][Full Text] [Related]  

  • 10. NMR-Based Analysis of Nanobodies to SARS-CoV-2 Nsp9 Reveals a Possible Antiviral Strategy Against COVID-19.
    Esposito G; Hunashal Y; Percipalle M; Venit T; Dieng MM; Fogolari F; Hassanzadeh G; Piano F; Gunsalus KC; Idaghdour Y; Percipalle P
    Adv Biol (Weinh); 2021 Dec; 5(12):e2101113. PubMed ID: 34705339
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Structural, energetic and lipophilic analysis of SARS-CoV-2 non-structural protein 9 (NSP9).
    de O Araújo J; Pinheiro S; Zamora WJ; Alves CN; Lameira J; Lima AH
    Sci Rep; 2021 Nov; 11(1):23003. PubMed ID: 34837010
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Multi-targeting approach for nsp3, nsp9, nsp12 and nsp15 proteins of SARS-CoV-2 by Diosmin as illustrated by molecular docking and molecular dynamics simulation methodologies.
    Kumar S; Sharma PP; Upadhyay C; Kempaiah P; Rathi B; Poonam
    Methods; 2021 Nov; 195():44-56. PubMed ID: 33639316
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Exploring potential inhibitor of SARS-CoV2 replicase from FDA approved drugs using insilico drug discovery methods.
    Chandra A; Gurjar V; Ahmed MZ; Alqahtani AS; Qamar I; Singh N
    J Biomol Struct Dyn; 2022 Aug; 40(12):5507-5514. PubMed ID: 33491573
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Collision-Induced Affinity Selection Mass Spectrometry for Identification of Ligands.
    Mak T; Rossjohn J; Littler DR; Liu M; Quinn RJ
    ACS Bio Med Chem Au; 2022 Oct; 2(5):450-455. PubMed ID: 37101899
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficient discovery of potential inhibitors for SARS-CoV-2 3C-like protease from herbal extracts using a native MS-based affinity-selection method.
    Zhu D; Su H; Ke C; Tang C; Witt M; Quinn RJ; Xu Y; Liu J; Ye Y
    J Pharm Biomed Anal; 2022 Feb; 209():114538. PubMed ID: 34929567
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A Biochemical and Biophysical Analysis of the Interaction of nsp9 with nsp12 from SARS-CoV-2-Implications for Future Drug Discovery Efforts.
    Baker DL; Wang B; Wilkinson-White LE; El-Kamand S; Allport TA; Ataide SF; Kwan AH; Artsimovitch I; Cubeddu L; Gamsjaeger R
    Proteins; 2024 Jul; ():. PubMed ID: 38958516
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Chemical proteomics reveals HSP70 1A as a target for the anticancer diterpene oridonin in Jurkat cells.
    Dal Piaz F; Cotugno R; Lepore L; Vassallo A; Malafronte N; Lauro G; Bifulco G; Belisario MA; De Tommasi N
    J Proteomics; 2013 Apr; 82():14-26. PubMed ID: 23416714
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Virtual screening of phytochemicals by targeting multiple proteins of severe acute respiratory syndrome coronavirus 2: Molecular docking and molecular dynamics simulation studies.
    Azeem M; Mustafa G; Mahrosh HS
    Int J Immunopathol Pharmacol; 2022; 36():3946320221142793. PubMed ID: 36442514
    [TBL] [Abstract][Full Text] [Related]  

  • 19. SND1 binds SARS-CoV-2 negative-sense RNA and promotes viral RNA synthesis through NSP9.
    Schmidt N; Ganskih S; Wei Y; Gabel A; Zielinski S; Keshishian H; Lareau CA; Zimmermann L; Makroczyova J; Pearce C; Krey K; Hennig T; Stegmaier S; Moyon L; Horlacher M; Werner S; Aydin J; Olguin-Nava M; Potabattula R; Kibe A; Dölken L; Smyth RP; Caliskan N; Marsico A; Krempl C; Bodem J; Pichlmair A; Carr SA; Chlanda P; Erhard F; Munschauer M
    Cell; 2023 Oct; 186(22):4834-4850.e23. PubMed ID: 37794589
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mechanistic and thermodynamic characterization of antiviral inhibitors targeting nucleocapsid N-terminal domain of SARS-CoV-2.
    Dhaka P; Singh A; Choudhary S; Peddinti RK; Kumar P; Sharma GK; Tomar S
    Arch Biochem Biophys; 2023 Dec; 750():109820. PubMed ID: 37956938
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.